Creutzfeldt-Jakob disease

Changed by Frank Gaillard, 23 Sep 2021

Updates to Article Attributes

Body was changed:

Show markup changes

Creutzfeldt-Jakob disease (CJD) is a transmissible spongiform encephalopathy that results in a rapidly progressive dementia and death usually within a year from onset. The vast majority are sporadic, but familial and acquired forms are occasionally encountered.

On imaging, it classically manifests as hyperintense signal on DWI (and usually FLAIR) in regions of the cerebral grey matter (cortex, followed by the striatum, followed by thalamus).

Epidemiology

Four types of Creutzfeldt-Jakob disease have been described ^2,6:

sporadic (sCJD)
- accounts for 85-90% of cases
- further divided into numerous subtypes according to molecular markers (see pathology section below)
variant (vCJD)
- bovine-to-human transmission of bovine spongiform encephalopathy (a.k.a. "mad cow disease"): considered zoonotic by some
- especially if in the UK between 1981-1996
- subsequent human-to-human transmission (e.g. transfusion) of vCJD
familial (fCJD)
- 10% of cases
- these individuals carry a PRPc mutation
iatrogenic (iCJD)
- following administration of cadaveric human pituitary hormones (pre-1985)
- various transplants

Clinical presentation

Sporadic Creutzfeldt-Jakob disease is characterised by rapidly progressive dementia and other features of neuropsychiatric decline resulting in death within a year of onset. Other common features include myoclonus, visual hallucinations, cerebellar dysfunction (such as ataxia and nystagmus), pyramidal or extrapyramidal signs (such as spasticity, rigidity, dystonia, or bradykinesia), and eventually akinetic mutism ²².

The Heidenhain variant presents as isolated visual symptoms such as impaired visual acuity, distortions of shapes and colors, and visual hallucinations.

The Brownell-Oppenheimer variant presents as isolated cerebellar ataxia.

Variant Creutzfeldt-Jakob disease presents mostly with psychiatric symptoms (such as depression) and sensory symptoms (dysesthesias or paresthesias).

Diagnostic markers

characteristic results on electroencephalography (EEG)
S100
CSF 14-3-3 protein: positive result in a patient suspected clinically of having sCJD
CSF and/or olfactory mucosa real ~~time~~-time quaking-induced conversion (RT-QuIC) seeding assays: detects minute amounts of the disease-specific pathologic prion protein ^12,13
- found to be more sensitive than CSF 14-3-3 protein titres ¹²

A definitive diagnosis requires a brain biopsy, although in many institutions the difficulty involved in sterilising equipment renders a biopsy undesirable.

Pathology

CJD is ~~thought to be~~ mediated via prions, a type of protein, which manifests in sheep as the disease scrapie, and in cows as bovine spongiform encephalopathy. Prions are considered infectious in the sense that they can alter the structure of neighbouring proteins.

CJD leads to spongiform degeneration of the brain, which is thought to be caused by the conversion of normal prion protein to proteinaceous infectious particles that accumulate in and around neurons and lead to cell death.

Classification

A number of subtypes of sporadic CJD are recognised based on molecular markers, and these have distinct clinical and pathological features. The classification is based on ^16,17:

codon 129 in the prion protein gene
- methionine (M) or valine (V)
size of the protease-resistant core of the abnormal prion protein
- PrPSc type 1 (21 kDa) or type 2 (19 kDa)

Each variant of sporadic CJD results from the combination of codon 129 genotype (M or V) and PrPSc type (1, 2 or 1 + 2) ^16,17.

Additionally, the MM2 subtype as has been noted to have distinctive histopathological features affecting the cerebral cortex ~~and~~or the thalamus and have therefore been separated into MM2 cortical (MM2C) and MM2 thalamic (MM2T).

Mixed types are also encountered. The result is that there is significant variation in the literature in regards to how many subtypes there are and if and how they should be grouped together ¹⁷.

Clinical patterns have been linked to various molecular subtypes (e.g. Heidenhain variant linked to MM1 and MM2C ¹⁸, and Brownell-Oppenheimer variant linked to VV2 ^19,20).

Radiographic features

Specific sites of imaging abnormality are typical of sporadic Creutzfeldt-Jakob disease ²²:

cerebral cortex (most common) ⁵:
- most common: insula, cingulate gyrus, superior frontal gyrus
- common: precuneus, cuneus, paracentral lobule, medial frontal gyrus, occipital gyri, angular/supramarginal gyrus, superior parietal lobule, inferior frontal gyrus
- less common: postcentral gyrus, precentral gyrus, medial and superior temporal gyri
deep ~~gray~~grey matter
- most common: striatum (caudate and putamen)
- common: thalamus

Involvement is usually bilateral but may be asymmetric or symmetric ⁵. The extent of abnormality increases as the disease progresses.

The Heidenhain variant of sporadic Creutzfeldt-Jakob disease predominantly involves the parieto-occipital cortex.

Variant Creutzfeldt-Jakob disease characteristically shows the hockey stick sign and/or pulvinar sign of thalamic involvement. However, thalamic involvement is not pathognomonic of variant disease and is more commonly seen with sporadic Creutzfeldt-Jakob disease due to the overall greater prevalence of the sporadic CJD ²².

MRI

Cerebral ~~gray~~grey matter findings are detected on the following sequences ^8,22:

DWI~~/ADC~~: ~~restricted diffusion~~hyperintensity (most sensitive) and more pronounced than T2/FLAIR changes
ADC: reduced values (restricted diffusion)
T2-FLAIR: hyperintensity

Signal abnormalities may be subtle initially but become more pronounced as the disease progresses. Review of sequential studies also typically demonstrates rapidly progressive cerebral atrophy.

An unusual finding associated with sporadic Creutzfeldt-Jakob disease is intrinsic T1 hyperintensity in the globus pallidus ²².

Cerebellar involvement, including in the Brownell-Oppenheimer variant, is primarily detected as atrophy; DWI is insensitive here ²³.

Nuclear medicine

Fluorine-18-FDG PET shows hypometabolism in the affected regions.

Treatment and prognosis

There is currently no curative treatment and the disease is invariably fatal with a mean survival of only seven months.

Creutzfeldt-Jakob disease is a notifiable disease in most countries, including European Union countries, Australia, United Kingdom, USA, and Canada.

History and etymology

It was named after Hans Gerhard Creutzfeldt (1885-1964), a German neurologist who first described the condition in 1920, and Alfons Maria Jakob (1884-1931), a German neurologist who also described the condition in a separate study in 1921 ^14,15.

Differential diagnosis

MRI imaging features overlap with many other conditions but the presentation will be different ^108,10,11,21:

autoimmune encephalitis
- particularly anti-D2 dopamine antibodies
- T2 signal change is dominant, with only minor, if any, diffusion change
hypoxic/anoxic brain injury
osmotic demyelination
encephalitis
hepatic encephalopathy
hypoglycaemic encephalopathy
mitochondrial disease

-<p><strong>Creutzfeldt-Jakob disease </strong>(<strong>CJD</strong>) is a spongiform encephalopathy that results in a rapidly progressive dementia and death usually within a year from onset. The vast majority are sporadic, but familial and acquired forms are occasionally encountered.</p><p>On imaging, it classically manifests as hyperintense signal on DWI (and usually FLAIR) in regions of the cerebral grey matter (cortex, followed by striatum, followed by thalamus).</p><h4>Epidemiology</h4><p>Four types of Creutzfeldt-Jakob disease have been described <sup>2,6</sup>:</p><ul>
+<p><strong>Creutzfeldt-Jakob disease </strong>(<strong>CJD</strong>) is a <a title="Transmissible spongiform encephalopathies" href="/articles/prion-diseases">transmissible spongiform encephalopathy </a>that results in rapidly progressive dementia and death usually within a year from onset. The vast majority are sporadic, but familial and acquired forms are occasionally encountered.</p><p>On imaging, it classically manifests as hyperintense signal on DWI (and usually FLAIR) in regions of the cerebral grey matter (cortex, followed by the striatum, followed by thalamus).</p><h4>Epidemiology</h4><p>Four types of Creutzfeldt-Jakob disease have been described <sup>2,6</sup>:</p><ul>
-</ul><h4>Clinical presentation</h4><p>Sporadic Creutzfeldt-Jakob disease is characterised by rapidly progressive dementia and other features of neuropsychiatric decline resulting in death within a year of onset. Other common features include myoclonus, visual hallucinations, cerebellar dysfunction (such as ataxia and nystagmus), pyramidal or extrapyramidal signs (such as spasticity, rigidity, dystonia, or bradykinesia), and eventually akinetic mutism <sup>22</sup>.</p><p>The <a href="/articles/heidenhain-variant-of-sporadic-creutzfeldt-jakob-disease">Heidenhain variant</a> presents as isolated visual symptoms such as impaired visual acuity, distortions of shapes and colors, and visual hallucinations.</p><p>The <a href="/articles/brownell-oppenheimer-variant-of-sporadic-creutzfeldt-jakob-disease">Brownell-Oppenheimer variant</a> presents as isolated cerebellar ataxia.</p><p>Variant Creutzfeldt-Jakob disease presents mostly with psychiatric symptoms (such as depression) and sensory symptoms (dysesthesias or paresthesias).</p><p></p><h5>Diagnostic markers</h5><ul>
+</ul><h4>Clinical presentation</h4><p>Sporadic Creutzfeldt-Jakob disease is characterised by rapidly progressive dementia and other features of neuropsychiatric decline resulting in death within a year of onset. Other common features include myoclonus, visual hallucinations, cerebellar dysfunction (such as ataxia and nystagmus), pyramidal or extrapyramidal signs (such as spasticity, rigidity, dystonia, or bradykinesia), and eventually akinetic mutism <sup>22</sup>.</p><p>The <a href="/articles/heidenhain-variant-of-sporadic-creutzfeldt-jakob-disease">Heidenhain variant</a> presents as isolated visual symptoms such as impaired visual acuity, distortions of shapes and colors, and visual hallucinations.</p><p>The <a href="/articles/brownell-oppenheimer-variant-of-sporadic-creutzfeldt-jakob-disease">Brownell-Oppenheimer variant</a> presents as isolated cerebellar ataxia.</p><p>Variant Creutzfeldt-Jakob disease presents mostly with psychiatric symptoms (such as depression) and sensory symptoms (dysesthesias or paresthesias).</p><p></p><h5>Diagnostic markers</h5><ul>
~~-<li>CSF <a href="/articles/14-3-3-protein-1">14-3-3 protein</a>: positive result in patient suspected clinically of having sCJD</li>~~
-<li>CSF and/or olfactory mucosa real time quaking-induced conversion (RT-QuIC) seeding assays: detects minute amounts of the disease-specific pathologic prion protein <sup>12,13</sup><ul><li>found to be more sensitive than CSF 14-3-3 protein titres <sup>12</sup>
+<li>CSF <a href="/articles/14-3-3-protein-1">14-3-3 protein</a>: positive result in a patient suspected clinically of having sCJD</li>
+<li>CSF and/or olfactory mucosa real-time quaking-induced conversion (RT-QuIC) seeding assays: detects minute amounts of the disease-specific pathologic prion protein <sup>12,13</sup><ul><li>found to be more sensitive than CSF 14-3-3 protein titres <sup>12</sup>
-</ul><p>A definitive diagnosis requires a brain biopsy, although in many institutions the difficulty involved in sterilising equipment renders a biopsy undesirable. </p><h4>Pathology</h4><p>CJD is thought to be mediated via <a href="/articles/prion-diseases">prions</a>, a type of protein, which manifests in sheep as the disease scrapie, and in cows as bovine spongiform encephalopathy. Prions are considered infectious in the sense that they can alter the structure of neighbouring proteins. </p><p>CJD leads to spongiform degeneration of the brain, which is thought to be caused by the conversion of normal prion protein to proteinaceous infectious particles that accumulate in and around neurons and lead to cell death.</p><h5>Classification</h5><p>A number of subtypes of sporadic CJD are recognised based on molecular markers, and these have distinct clinical and pathological features. The classification is based on <sup>16,17</sup>:</p><ul>
+</ul><p>A definitive diagnosis requires a brain biopsy, although in many institutions the difficulty involved in sterilising equipment renders a biopsy undesirable. </p><h4>Pathology</h4><p>CJD is mediated via <a href="/articles/prion-diseases">prions</a>, a type of protein, which manifests in sheep as the disease scrapie, and in cows as bovine spongiform encephalopathy. Prions are considered infectious in the sense that they can alter the structure of neighbouring proteins. </p><p>CJD leads to spongiform degeneration of the brain, which is thought to be caused by the conversion of normal prion protein to proteinaceous infectious particles that accumulate in and around neurons and lead to cell death.</p><h5>Classification</h5><p>A number of subtypes of sporadic CJD are recognised based on molecular markers, and these have distinct clinical and pathological features. The classification is based on <sup>16,17</sup>:</p><ul>
-</ul><p>Each variant of sporadic CJD results from the combination of codon 129 genotype (M or V) and PrPSc type (1, 2 or 1 + 2) <sup>16,17</sup>. </p><p>Additionally, MM2 subtype as has been noted to have distinctive histopathological features affecting the cerebral cortex and the thalamus and have therefore been separated into MM2 cortical (MM2C) and MM2 thalamic (MM2T).</p><p>Mixed types are also encountered. The result is that there is significant variation in the literature in regards to how many subtypes there are and if and how they should be grouped together <sup>17</sup>.</p><p>Clinical patterns have been linked to various molecular subtypes (e.g. <a href="/articles/heidenhain-variant-of-sporadic-creutzfeldt-jakob-disease">Heidenhain variant</a> linked to MM1 and MM2C <sup>18</sup>, and <a href="/articles/brownell-oppenheimer-variant-of-sporadic-creutzfeldt-jakob-disease">Brownell-Oppenheimer variant</a> linked to VV2 <sup>19,20</sup>).</p><h4>Radiographic features</h4><p>Specific sites of imaging abnormality are typical of sporadic Creutzfeldt-Jakob disease <sup>22</sup>:</p><ul>
+</ul><p>Each variant of sporadic CJD results from the combination of codon 129 genotype (M or V) and PrPSc type (1, 2 or 1 + 2) <sup>16,17</sup>. </p><p>Additionally, the MM2 subtype has been noted to have distinctive histopathological features affecting the cerebral cortex or the thalamus and have therefore been separated into MM2 cortical (MM2C) and MM2 thalamic (MM2T).</p><p>Mixed types are also encountered. The result is that there is significant variation in the literature in regards to how many subtypes there are and if and how they should be grouped together <sup>17</sup>.</p><p>Clinical patterns have been linked to various molecular subtypes (e.g. <a href="/articles/heidenhain-variant-of-sporadic-creutzfeldt-jakob-disease">Heidenhain variant</a> linked to MM1 and MM2C <sup>18</sup>, and <a href="/articles/brownell-oppenheimer-variant-of-sporadic-creutzfeldt-jakob-disease">Brownell-Oppenheimer variant</a> linked to VV2 <sup>19,20</sup>).</p><h4>Radiographic features</h4><p>Specific sites of imaging abnormality are typical of sporadic Creutzfeldt-Jakob disease <sup>22</sup>:</p><ul>
~~-<a title="cerebral cortex" href="/articles/cerebral-cortex">cerebral cortex</a> (most common) <sup>5</sup>:<ul>~~
+<a href="/articles/cerebral-cortex">cerebral cortex</a> (most common) <sup>5</sup>:<ul>
-<li>common: <a href="/articles/precuneus">precuneus</a>, <a href="/articles/cuneus">cuneus</a>, <a href="/articles/paracentral-lobule">paracentral lobule</a>, <a href="/articles/medial-frontal-gyrus">medial frontal gyrus</a>, <a href="/articles/occipital-lobe">occipital</a> gyri, <a href="/articles/angular-gyrus">angular</a>/<a href="/articles/supramarginal-gyrus-1">supramarginal</a> gyrus, <a href="/articles/superior-parietal-lobule">superior parietal lobule</a>, <a href="/articles/inferior-frontal-gyrus">inferior frontal gyrus</a>
+<li>common: <a href="/articles/precuneus-1">precuneus</a>, <a href="/articles/cuneus">cuneus</a>, <a href="/articles/paracentral-lobule">paracentral lobule</a>, <a href="/articles/medial-frontal-gyrus">medial frontal gyrus</a>, <a href="/articles/occipital-lobe">occipital</a> gyri, <a href="/articles/angular-gyrus">angular</a>/<a href="/articles/supramarginal-gyrus-1">supramarginal</a> gyrus, <a href="/articles/superior-parietal-lobule">superior parietal lobule</a>, <a href="/articles/inferior-frontal-gyrus">inferior frontal gyrus</a>
~~-<li>deep gray matter<ul>~~
+<li>deep grey matter<ul>
-</ul><p>Involvement is usually bilateral but may be asymmetric or symmetric <sup>5</sup>. The extent of abnormality increases as the disease progresses.</p><p>The <a href="/articles/heidenhain-variant-of-sporadic-creutzfeldt-jakob-disease">Heidenhain variant</a> of sporadic Creutzfeldt-Jakob disease predominantly involves the parieto-occipital cortex.</p><p>Variant Creutzfeldt-Jakob disease characteristically shows the <a href="/articles/hockey-stick-sign-creutzfeldt-jakob-disease">hockey stick sign</a> and/or <a href="/articles/pulvinar-sign-creutzfeldt-jakob-disease">pulvinar sign</a> of thalamic involvement. However, thalamic involvement is not pathognomonic of variant disease and is more commonly seen with sporadic Creutzfeldt-Jakob disease <sup>22</sup>.</p><h5>MRI</h5><p>Cerebral gray matter findings are detected on the following sequences <sup>8,22</sup>:</p><ul>
+</ul><p>Involvement is usually bilateral but may be asymmetric or symmetric <sup>5</sup>. The extent of abnormality increases as the disease progresses.</p><p>The <a href="/articles/heidenhain-variant-of-sporadic-creutzfeldt-jakob-disease">Heidenhain variant</a> of sporadic Creutzfeldt-Jakob disease predominantly involves the parieto-occipital cortex.</p><p>Variant Creutzfeldt-Jakob disease characteristically shows the <a href="/articles/hockey-stick-sign-creutzfeldt-jakob-disease">hockey stick sign</a> and/or <a href="/articles/pulvinar-sign-creutzfeldt-jakob-disease">pulvinar sign</a> of thalamic involvement. However, thalamic involvement is not pathognomonic of variant disease and is more commonly seen with sporadic Creutzfeldt-Jakob disease due to the overall greater prevalence of the sporadic CJD <sup>22</sup>.</p><h5>MRI</h5><p>Cerebral grey matter findings are detected on the following sequences <sup>8,22</sup>:</p><ul>
~~-<strong>DWI/ADC</strong>: restricted diffusion (most sensitive)</li>~~
+<strong>DWI</strong>: hyperintensity (most sensitive) and more pronounced than T2/FLAIR changes</li>
+<li>
+<strong>ADC</strong>: reduced values (restricted diffusion)</li>
-</ul><p>Signal abnormalities may be subtle initially but become more pronounced as disease progresses. Review of sequential studies also typically demonstrates rapidly progressive cerebral atrophy.</p><p>An unusual finding associated with sporadic Creutzfeldt-Jakob disease is intrinsic T1 hyperintensity in the <a href="/articles/globus-pallidus">globus pallidus</a> <sup>22</sup>.</p><p>Cerebellar involvement, including in the <a href="/articles/brownell-oppenheimer-variant-of-sporadic-creutzfeldt-jakob-disease">Brownell-Oppenheimer variant</a>, is primarily detected as atrophy; DWI is insensitive here <sup>23</sup>.</p><h5>Nuclear medicine </h5><p><a href="/articles/f-18-fluorodeoxyglucose">Fluorine-18-FDG PET</a> shows hypometabolism in the affected regions.</p><h4>Treatment and prognosis</h4><p>There is currently no curative treatment and the disease is invariably fatal with a mean survival of only seven months.</p><p>Creutzfeldt-Jakob disease is a <a href="/articles/notifiable-disease">notifiable disease</a> in most countries, including European Union countries, Australia, United Kingdom, USA, and Canada.</p><h4>History and etymology</h4><p>It was named after <strong>Hans Gerhard Creutzfeldt</strong> (1885-1964), a German neurologist who first described the condition in 1920, and <strong>Alfons Maria Jakob</strong> (1884-1931), a German neurologist who also described the condition in a separate study in 1921 <sup>14,15</sup>. </p><h4>Differential diagnosis</h4><p>MRI imaging features overlap with many other conditions but the presentation will be different <sup>10,11,21</sup>:</p><ul>
+</ul><p>Signal abnormalities may be subtle initially but become more pronounced as the disease progresses. Review of sequential studies also typically demonstrates rapidly progressive cerebral atrophy.</p><p>An unusual finding associated with sporadic Creutzfeldt-Jakob disease is intrinsic T1 hyperintensity in the <a href="/articles/globus-pallidus">globus pallidus</a> <sup>22</sup>.</p><p>Cerebellar involvement, including in the <a href="/articles/brownell-oppenheimer-variant-of-sporadic-creutzfeldt-jakob-disease">Brownell-Oppenheimer variant</a>, is primarily detected as atrophy; DWI is insensitive here <sup>23</sup>.</p><h5>Nuclear medicine </h5><p><a href="/articles/f-18-fluorodeoxyglucose">Fluorine-18-FDG PET</a> shows hypometabolism in the affected regions.</p><h4>Treatment and prognosis</h4><p>There is currently no curative treatment and the disease is invariably fatal with a mean survival of only seven months.</p><p>Creutzfeldt-Jakob disease is a <a href="/articles/notifiable-disease">notifiable disease</a> in most countries, including European Union countries, Australia, United Kingdom, USA, and Canada.</p><h4>History and etymology</h4><p>It was named after <strong>Hans Gerhard Creutzfeldt</strong> (1885-1964), a German neurologist who first described the condition in 1920, and <strong>Alfons Maria Jakob</strong> (1884-1931), a German neurologist who also described the condition in a separate study in 1921 <sup>14,15</sup>. </p><h4>Differential diagnosis</h4><p>MRI imaging features overlap with many other conditions but the presentation will be different <sup>8,10,11,21</sup>:</p><ul>
~~-<li>T2 signal change is dominant, with only minor if any diffusion change</li>~~
+<li>T2 signal change is dominant, with only minor, if any, diffusion change</li>
~~-<li><a href="/articles/mitochondrial-disorders">mitochondrial disease</a></li>~~
+<li><a href="/articles/primary-mitochondrial-disorders">mitochondrial disease</a></li>

References changed:

8. Vitali P, Maccagnano E, Caverzasi E et al. Diffusion-Weighted MRI Hyperintensity Patterns Differentiate CJD from Other Rapid Dementias. Neurology. 2011;76(20):1711-9. <a href="https://doi.org/10.1212/wnl.0b013e31821a4439">doi:10.1212/wnl.0b013e31821a4439</a>
8. Vitali P, Maccagnano E, Caverzasi E et-al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology. 2011;76 (20): 1711-9. <a href="http://dx.doi.org/10.1212/WNL.0b013e31821a4439">doi:10.1212/WNL.0b013e31821a4439</a> - <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100134">Free text at pubmed</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/21471469">Pubmed citation</a><div class="ref_v2"></div>

ADVERTISEMENT: Supporters see fewer/no ads

{"current_user":null,"inclusions":[{"imageId":487520,"studyId":10588,"caseSlug":"sporadic-creutzfeldt-jakob-disease","caption":"Case 1","thumbnail":"https://prod-images-static.radiopaedia.org/images/487520/add208e6e5a6eb89bd96c5bb1dda65_big_gallery.jpg","isStack":false,"diagnosticCertainty":"probable"},{"imageId":1626141,"studyId":16003,"caseSlug":"sporadic-creutzfeldtjakob-disease","caption":"Case 2","thumbnail":"https://prod-images-static.radiopaedia.org/images/1626141/4f676ffc4977b3f892777411b64009_big_gallery.jpg","isStack":false,"diagnosticCertainty":"probable"},{"imageId":2150774,"studyId":18615,"caseSlug":"creutzfeldt-jakob-disease","caption":"Case 3","thumbnail":"https://prod-images-static.radiopaedia.org/images/2150774/e1a6067d3c0f46d76e7eb03cb66c3286a442b110b489b584dbaf6e56c2e5c00f_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":3017316,"studyId":22076,"caseSlug":"creutzfeldt-jakob-disease-sporadic","caption":"Case 4","thumbnail":"https://prod-images-static.radiopaedia.org/images/3017316/85f845ba495c418099640f5208c27c_big_gallery.jpg","isStack":true,"diagnosticCertainty":"confirmed_unsubstantiated"},{"imageId":7151612,"studyId":29852,"caseSlug":"creutzfeldt-jakob-disease-cjd","caption":"Case 5","thumbnail":"https://prod-images-static.radiopaedia.org/images/7151612/27e0085dd32afe11694b7cbf0ccd892e559c8077819e02ac5030c5a426000de4_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":17610176,"studyId":44074,"caseSlug":"creutzfeldt-jakob-disease-cjd-2","caption":"Case 6","thumbnail":"https://prod-images-static.radiopaedia.org/images/17610176/265872499d5882fa7ebfd71a8e787f_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":20562294,"studyId":47122,"caseSlug":"creutzfeldt-jakob-disease-2","caption":"Case 7","thumbnail":"https://prod-images-static.radiopaedia.org/images/20562294/e011c5fd998009137566714d988f39_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":22864945,"studyId":49672,"caseSlug":"creutzfeldt-jakob-disease-cjd-3","caption":"Case 8","thumbnail":"https://prod-images-static.radiopaedia.org/images/22864945/f7816ccc807fb2001ce136e3a9129b_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":22060750,"studyId":48714,"caseSlug":"creutzfeldt-jakob-disease-5","caption":"Case 9","thumbnail":"https://prod-images-static.radiopaedia.org/images/22060750/7906a5be599339ada3fe3ee59677bc_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_unsubstantiated"},{"imageId":30386501,"studyId":59634,"caseSlug":"creutzfeldt-jakob-disease-6","caption":"Case 10","thumbnail":"https://prod-images-static.radiopaedia.org/images/30386501/f0b8b0b86225e0bb22c13d1fb8575c_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":20965794,"studyId":47486,"caseSlug":"creutzfeldt-jakob-disease-4","caption":"Case 11","thumbnail":"https://prod-images-static.radiopaedia.org/images/20965794/3a97076149a859c77c4569b90d6634_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_unsubstantiated"},{"imageId":11504560,"studyId":29930,"caseSlug":"creutzfeldt-jacob-disease-cjd","caption":"Case 12","thumbnail":"https://prod-images-static.radiopaedia.org/images/11504560/9bfd71bf825a5070b63514b24ee2cf_big_gallery.jpg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":8540873,"studyId":32014,"caseSlug":"creutzfeldt-jakob-disease-cjd-1","caption":"Case 13","thumbnail":"https://prod-images-static.radiopaedia.org/images/8540873/242c31865d1bb727971c9bad5620a8_big_gallery.jpg","isStack":true,"diagnosticCertainty":"confirmed_unsubstantiated"},{"imageId":31119311,"studyId":60388,"caseSlug":"creutzfeldt-jakob-disease-8","caption":"Case 14","thumbnail":"https://prod-images-static.radiopaedia.org/images/31119311/d3ad2a7a19dd814cb4ec1f4caf1c2a1ddd687fd508f8c410b686ea14bc0a50b3_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":51994939,"studyId":84828,"caseSlug":"creutzfeldt-jakob-disease-14","caption":"Case 15","thumbnail":"https://prod-images-static.radiopaedia.org/images/51994939/cb41e7abf2f4a1898ba279b1222051_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_unsubstantiated"},{"imageId":52990902,"studyId":92399,"caseSlug":"creutzfeldt-jakob-disease-15","caption":"Case 16","thumbnail":"https://prod-images-static.radiopaedia.org/images/52990902/90eae23cc846078a722b3a9e7e2ac0_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"probable"},{"imageId":53456467,"studyId":95865,"caseSlug":"creutzfeldt-jakob-disease-16","caption":"Case 17","thumbnail":"https://prod-images-static.radiopaedia.org/images/53456467/9_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":62835633,"studyId":138805,"caseSlug":"creutzfeldt-jakob-disease-26","caption":"Case 18","thumbnail":"https://prod-images-static.radiopaedia.org/images/62835633/808877ccea48d9f4ced1d827914ea8c623e0d2aecaed21ac64de31cfd129efe4_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":57464712,"studyId":118914,"caseSlug":"sporadic-creutzfeld-jakob-disease-1","caption":"Case 19","thumbnail":"https://prod-images-static.radiopaedia.org/images/57464712/8d98720019a42d88bbc0778af9dc550a9c477a47762b6ae272c2069e3e002625_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_unsubstantiated"}],"ddx_inclusions":[{"imageId":15232834,"studyId":41219,"caseSlug":"acute-severe-hepatic-encephalopathy","caption":"Acute severe hepatic encephalopathy","thumbnail":"https://prod-images-static.radiopaedia.org/images/15232834/653e08dbde904fae3627174351215e_big_gallery.jpg","isStack":true,"diagnosticCertainty":"confirmed_unsubstantiated"},{"imageId":5029136,"studyId":25897,"caseSlug":"hypoxic-ischaemic-brain-damage","caption":"Hypoxic-ischemic brain damage","thumbnail":"https://prod-images-static.radiopaedia.org/images/5029136/8dfb9d857b84f84eb868683b05c5078a82111f42a89889fc829d98f558cb9872_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_unsubstantiated"},{"imageId":15396138,"studyId":41374,"caseSlug":"hypoglycaemic-encephalopathy-4","caption":"Hypoglycemic encephalopathy","thumbnail":"https://prod-images-static.radiopaedia.org/images/15396138/8003d16b14f90161125cb03d8e6769_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":61273723,"studyId":132731,"caseSlug":"uraemic-encephalopathy-5","caption":"Uremic encephalopathy","thumbnail":"https://prod-images-static.radiopaedia.org/images/61273723/13c4a4f6ad18b044233d3222fb01d112acf05feb7f98bd7f108cbbdc67286cf7_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_unsubstantiated"},{"imageId":61365533,"studyId":133020,"caseSlug":"myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-2","caption":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","thumbnail":"https://prod-images-static.radiopaedia.org/images/61365533/28ac03a6896f30cccd837b082db969528ae2cba65cda7b91283de66ec7161325_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":61094846,"studyId":131994,"caseSlug":"organophosphate-poisoning","caption":"Organophosphate poisoning","thumbnail":"https://prod-images-static.radiopaedia.org/images/61094846/0426faa8c162afee3f32c19800000742cb06fc2b957c7eb6d801416fadb026eb_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_substantiated"},{"imageId":61026841,"studyId":131761,"caseSlug":"carbon-monoxide-poisoning-17","caption":"Carbon monoxide poisoning","thumbnail":"https://prod-images-static.radiopaedia.org/images/61026841/b00db41be7d9505a55dad90ce0d8da8f6e773384badd1ad7cbdc8448feba60c6_big_gallery.jpeg","isStack":true,"diagnosticCertainty":"confirmed_unsubstantiated"}],"lang":"us"}